

ASENT 2024 ANNUAL MEETING



GLOBAL NEUROTHERAPEUTICS
CONFERENCE
MARCH 12 - 14, 2024

HYATT REGENCY BETHESDA,
BETHESDA, MD



ADVANCE PROGRAM



Andrew J. Cole, M.D., F.R.C.P.(C.)
Professor of Neurology
Harvard Medical School
Director, MGH Epilepsy Service
Chief, Division of Clinical
Neurophysiology
Vice-Chair for External Affairs,
Dept. of Neurology
President, ASENT

Dear Colleagues,

After three years of very successful virtual Annual Meetings, we are thrilled to meet in person in 2024 in Bethesda. The ASENT2024 Annual Meeting will highlight the latest therapeutic advances in a broad range neurologic disease states, processes and delivery methods, including nine scientific symposia, a scientific debate, and a Covid update. A few highlights include:

On Thursday, March 14, 2024, the plenary session “Pre-clinical to First in Human in Drug Development” will feature Nathan Fountain, M.D., Thomas E. Worrell, Jr, Professor of Neurology and Epileptology at University of Virginia and Jim Doherty, Ph.D., of Sage Therapeutics to compare the similarities and differences in the preclinical process and infrastructure when developing a neurotherapeutic. As ASENT President, I will personally moderate this fireside chat style discussion.

The two additional unopposed plenary sessions will take place: “Fluid Biomarkers as Endpoints for Neurodegenerative Diseases” on Tuesday, March 12, 2024, and “Parkinson's Disease Biological Staging and Implications for Therapeutic Trials” on Wednesday, March 13, 2024. Other unopposed sessions include “NIH Update on COVID and CNS disease” with speaker Avindra Nath, M.D., Senior Investigator, NINDS, and a Beta Amyloid Debate

will be held Wednesday, March 13, 2024.

Attendees will also have an opportunity to hear top abstracts selected for presentation by the Abstract Review Committee. On Wednesday, March 13, 2024, as many as 20 selected abstracts will be presented as part of the ASENT Pipeline Datablitz. Abstracts qualify for an ASENT Pipeline Data Blitz presentation when they are submitted as an Abstract Submission. Abstracts can be submitted via <https://asent.org/AnnualMeeting2024>

Other special events include the Careers in Neuroscience Dinner, during which invited speakers showcase the wide range of career opportunities available in neuroscience related fields. Each presenter will take a few minutes to share an overview of their career and highlight any unique career opportunities they have discovered along the way. Participants and faculty from the Training in Neurotherapeutics Discovery and Development for Academic Scientists course also participate in this dynamic event. This reception and dinner are a wonderful way to kick off the meeting on Tuesday, March 12, 2024.

We are excited that the inaugural ASENT Training in Clinical Trials course will be held on Monday, March 12 - Tuesday, March 13, 2024, co-located with the Annual Meeting. Developed by ASENT leadership and led by outstanding faculty, this 1 ½ day course will introduce researchers and clinicians to the principles of neurotherapeutic clinical trial development and implementation.

Finally, ASENT continues its dedication to our international colleagues. We are pleased to welcome guests from the Japanese Society of Neurological Therapeutics and are honored to continue the tradition of neurological education and research among academic neurologists around the world. I, along with the Board of Directors and the Program Committee, invite you to make the most of this outstanding meeting.

Best,
Andrew J. Cole, M.D., F.R.C.P.(C.)
Harvard Medical School
President, ASENT

WHY ATTEND ASENT2024

ASENT2024 is the premier neurotherapeutics conference where senior leaders through junior faculty and trainees from across payers, providers, employers, investors, fast-growing startups, industry, academia, policymakers, funders and innovation centers gather to ask one question: how can we improve the process of the development and discovery of neurotherapeutics?

Attendees are often surprised to find that more than 50% of participants are practicing physicians and the caliber of speakers is outstanding for a conference that provides ample opportunity to connect, network and converse. Additionally the scientific content showcases the leading edge in neurotherapeutics including innovations across disease states, novel delivery systems, gene therapy, the latest drug therapies and devices. The event features plenary sessions, fireside chats, panel discussions, business roundtables, and networking meetings.

MEETING DETAILS

ASENT 2024 Meeting Dates

Tues, March 12 - Thurs, March 14, 2024

Registration Deadline

March 12, 2024

asent.org/annualmeeting2024

Hotel Reservation Deadline

February 10, 2024

Meeting Location

Hyatt Regency Bethesda
Metro Center, 1,
Bethesda, MD 20814

asent.org/annualmeeting2024

WHO ATTENDS

Clinician-

Investigators

Neuroscience

Trainees

Neuroscientist

Researchers

Industry

Research

Scientists

Clinicians

Advocacy Group

Leaders

Chairs of

Neurology

Chief Medical

Officers

Chief Scientific

Officers

CEOs

Founders

Funders

Investors

Payers

Innovation

Centers

CROs

Journal Editors

Health

Journalists

Drug and Device

Companies

Communication

Companies

Health Systems

FDA

NIH

All ARE

WELCOME!

50% ARE

Prescribers

WHAT IS ASENT?

The **American Society for Experimental Neurotherapeutics (ASENT)** is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders. Its primary goal is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system.

CONFERENCE INFORMATION AT A GLANCE

CONFERENCE DATES

March 12 - 14, 2024

PROGRAM

Registered sponsors are encouraged to attend all conference sessions, meals, receptions & events.

LOCATION

Hyatt Regency Bethesda
Bethesda, MD

REGISTRATION

Registration is open & is complimentary in most sponsorship packages.

HOUSING

Discounted housing is available at the Hyatt Regency Bethesda. Rates begin at \$219. Housing can be booked here: asent.org/annualmeeting2024

ABSTRACT SUBMISSION DATES

Opens: October 1, 2023

Closes: February 1, 2024

Submit your abstract here: asent.org/annualmeeting2024

PIPELINE SUBMISSION DATES

Opens: October 1, 2023

Closes: February 1, 2024

Submit your abstract here: asent.org/annualmeeting2024

OTHER ACTIVITIES

On March 11-12, The inaugural ASENT Clinical Trials Course will take place onsite. The Neurotherapeutics Drug Discovery and Development Course will run onsite March 12-15 as well.

REGISTRATION RATES

Early Bird Discount: Discounted Rates if purchased before December 31, 2023

MEMBER RATES

	Early Bird - (Now - Dec 31)	Standard - (Jan 1 - Mar 14)
AAN Member	\$150	\$250
Academic Member	\$175	\$275
Advocacy Member	\$75	\$175
Cinician Member	\$175	\$275
Government Member	\$175	\$275
Industry Member	\$325	\$425
JSNT Member	\$100	\$200
LMIC Member	\$50	\$150
Retired Member	\$150	\$250
Trainee Member	\$75	\$175

NONMEMBER RATES

	Early Bird - (Now - Dec 31)	Standard - (Jan 1 - Mar 14)
AAN NonMember	\$275	\$375
Academic NonMember	\$375	\$475
Advocacy NonMember	\$150	\$250
Clinician NonMember	\$375	\$475
Government NonMember	\$225	\$325
Industry NonMember	\$575	\$675
JSNT NonMember	\$175	\$275
LMIC NonMember	\$100	\$200
Retired NonMember	\$275	\$375
Trainee NonMember	\$150	\$250

Register at asent.org/annualmeeting2024

MONDAY, MARCH 11, 2024

7:00am - 5:30pm	ASENT Clinical Trials Course (APPLICATION ONLY)
5:30pm - 8:00pm	Reception and Dinner with Board and Program Committee

TUESDAY, MARCH 12, 2024

7:30am - 12:00pm	ASENT Clinical Trials Course (APPLICATION ONLY)
6:00pm - 8:00pm	Careers in Neuroscience Dinner

TUESDAY, MARCH 12, 2024

7:00am - 8:00am	Foyer Ballroom Level	Registration
7:00am - 8:00am	Foyer Ballroom Level	Breakfast
8:00am - 8:30 am	Regency 1	Presidential Welcome Remarks
8:30am - 10:30 am	Regency 1	<p>Symposium: Fluid Biomarkers as endpoints for neurodegenerative diseases</p> <p>This symposium is offered in partnership with the Japanese Society of Neurological Therapeutics. We are honored to have a long partnership with JSNT and pleased to present their delegate.</p> <p>DESCRIPTION: Fluid Biomarkers are being utilized to study neurodegenerative diseases, including Alzheimers and Parkinsons Disease.</p> <p>CHAIR: Gail Farfel, PhD, Consultant, Formerly CEO Promis Neurosciences</p> <p>FACULTY Dr. Ayami Okuzumi, Juntendo University School of Medicine, JSNT Presenter Henrik Zetterberg, University of Gothenburg (Sweden) Suzanne Hendriks, Pentara</p>
10:00am - 10:30am	Foyer Ballroom Level	Networking Break
10:30am - 12:00pm		<p>Symposium: Platform Clinical Trials in Neurology</p> <p>DESCRIPTION: The session will focus on how neurodegenerative disorders can benefit from platform designs using The HEALEY ALS Platform Trial as an example to showcase how the collaborative effort and enrollment in the trial can benefit neurotherapeutics trials.</p> <p>CHAIR: Merit Cudkowicz, MD, MSc, Harvard Medical School/MGH COCHAIR: Amir Tamiz, PhD, NINDS</p> <p>PRESENTATIONS: Clinton Wright, NINDS Merit Cudkowicz, Harvard Medical School/MGH Melanie Quintana, Berry Consultants</p> <p>PANEL DISCUSSION FEATURING Presenters as well as: Irfan Qureshi, M.D., CMO, Biohaven Teresa Buracchio, MD, CDER, FDA</p>

TUESDAY, MARCH 12, 2024

12:00pm - 1:30pm	Special Interest Group Lunches
1:30pm - 3:00pm	<p>CONCURRENT Symposium: Exosome in Neurotherapeutics</p> <p>DESCRIPTION: Extracellular vesicles (EVs) have wide-ranging implications in numerous disease areas. Targeting these EVs as a therapeutic strategy is an ever increasing field. During this symposium speakers will look at EV biomarkers, EVs as therapeutics, and EVs for the clinical and preclinical diagnosis of Alzheimer's disease and other neurological and psychiatric diseases.</p> <p>CHAIR: Dimitrios Kapogiannis, MD, National Institute on Aging COCHAIR: Carolyn Tallon, PhD, ALTPEP</p> <p>FACULTY: Dimitrios Kapogiannis, MD, National Institute on Aging Carlos Noguera-Ortiz, PhD, National Institute on Aging You Yang, PhD, Mayo Clinic College of Medicine and Science Mei Huang, PhD, Johns Hopkins Drug Discovery</p>
1:30pm - 3:00pm	<p>CONCURRENT Symposium: Digital Biomarkers in CNS clinical studies</p> <p>DESCRIPTION: The field of neuroscience is rapidly advancing with groundbreaking technologies and methodologies. In recent years, the emergence of digital biomarkers has revolutionized clinical studies in Central Nervous System disorders. This session will delve into the promising role of digital biomarkers in CNS clinical studies, exploring their potential to enhance diagnosis, monitoring, and treatment evaluation. During this session, esteemed experts in the field will present their latest research and share insights on the application of digital biomarkers across a range of CNS disorders. Attendees will gain a comprehensive understanding of the opportunities and challenges associated with leveraging digital biomarkers in clinical research.</p> <p>CHAIR: Bibi Bielokova, MD, NIAID COCHAIR: Sharon Tamir, MT-Pharma</p> <p>FACULTY: Rivka Kreitman, PhD, NeuralLight Jay Gupta, PhD, CDRH, FDA Dr. Ashkan Vaziri, Ph.D., BioSensics LLC</p>
3:00pm - 3:15pm	Networking Break
3:15pm - 5:00pm	<p>CONCURRENT Symposium: Opportunities to streamline development of gene therapies for rare diseases</p> <p>DESCRIPTION: A significant percentage of rare diseases affecting 30 million people in the US alone are neurological, and 90% of rare childhood disorders have major neurological effects. Many rare diseases stem from single-gene variations, they may be addressable using rapidly maturing genetic technologies, such as antisense oligonucleotides, small interfering RNAs, gene therapy and gene editing. Recent advances in gene therapies have encouraged the scientific community to pursue these treatments as disease modifying treatments that potentially bring significant benefit to the patients. This symposium will address end-to-end regulatory path for individualized gene therapies</p> <p>CHAIR: Gopa Raychaudhuri, PhD, Associate Director for Special Programs, FDA/CBER COCHAIR: Amir Tamiz, PhD, NINDS</p> <p>FACULTY: Lawrence Stark, PhD, Novartis Steven Gray, MD, UT Southwestern Philip J. Brooks, PhD, NIH/NCATS</p>

TUESDAY, MARCH 12, 2024

3:15pm - 5:00pm	<p>CONCURRENT Symposium: Current Research and Advances in Multiple Sclerosis</p> <p>DESCRIPTION: Microbial agents including viruses have long been incriminated as triggers in multiple sclerosis (MS). There is mounting evidence that EBV might play a role in MS pathogenesis. Stem cells transplantation therapy for MS is currently being evaluated in clinical trials including mesenchymal stem cell and autologous stem cells. The symposium will address advances in these three aspects of MS.</p> <p>CHAIR: Suhayl Dhib-Jalbut, MD, Rutgers School of Medicine COCHAIR: Steve Jacobson, PhD, NIH</p> <p>FACULTY: María Inés Gaitán, MD, NIH Steve Jacobson, PhD, NINDS Marjan Gharagozloo, Ph.D., Johns Hopkins</p>
5:00pm - 6:00pm	Cocktail Reception
6:00pm - 8:00pm	<p>ASENT Careers Dinner</p> <p>Each year ASENT invites a selection of speakers to informally share the trajectory of their career. We ask our speakers to come with no slides and a willingness to answer questions as there are many early career attendees in the audience.</p> <p>Speakers to be announced</p>

WEDNESDAY, MARCH 13, 2024

7:00am - 8:00am	Foyer Ballroom Level	Registration
7:00am - 8:00am	Foyer Ballroom Level	Breakfast
8:00am - 8:30 am	Regency 1	ASENT Business Meeting
8:30am - 10:00 am	Regency 1	<p>Symposium: Parkinson's disease biological staging and implications for therapeutic trials</p> <p>DESCRIPTION: Biological staging of Parkinson's disease is being proposed with use of imaging and cerebrospinal fluid biomarkers and prodromal clinical features. There is momentum in the field to define Parkinson's disease according to biological markers rather than traditional clinical features. This session seeks to explore the scientific, clinical, and regulatory issues surrounding pathways for therapeutics development using this framework.</p> <p>CHAIR: Ludy Shih, MD, MMSc, FAAN, FANA, Boston University School of Medicine COCHAIR: Kathleen Poston, M.D., M.S., Stanford University</p> <p>FACULTY Kathleen Poston, M.D., M.S., Stanford University Kevin Biglan, MD, MPH, Eli Lilly and Company Jennifer Goldman, MD, MS, Lewy Body Dementia Association</p>
10:00am - 10:30am	Foyer Ballroom Level	Networking Break

WEDNESDAY, MARCH 13, 2024

10:30am - 11:00am	<p>SPECIAL UPDATE: Covid CNS Update</p> <p>CHAIR: Debra J. Ehrlich, MD, MS, NINDS COCHAIR: Sharon Tamir, Mitsubishi Tanabe Pharma America</p> <p>FACULTY Avindra Nath, MD, NINDS</p>
11:00am - 11:30am	Pick up Lunch
11:30am - 1:00	<p>DEBATE: Beta Amyloid Debate</p> <p>CHAIR: Amir Tamiz, PhD, NIH COCHAIR: Dietrich Haubenberger, MD, Neurocrine Biosciences</p> <p>FACULTY Madhav Thambisetty, MD, PhD, NIH Gil Rabinovici, MD, FAAN, FANA, University of California, San Francisco</p>
1:00pm - 1:30pm	Networking Break
1:30pm - 3:00pm	<p>Pipeline Presentations</p> <p>Submitted abstracts that most closely conform to the ASENT Abstract criteria, showcase new and emerging data with scientific or clinical impact and align with ASENT goals may also be selected for a 10-minute oral presentation (including 2 minute Q&A) at one of our Pipeline Presentation sessions. ASENT encourages abstracts from private, public and startup companies, foundations and government or academic labs that contain neurotherapeutic research results.</p> <p>The ASENT Annual Meeting attracts leaders in neurotherapeutics from all over the world, in all disease states. Pipeline presentations increase exposure to strategic partners in life sciences who have supported novel approaches through partnerships or strategic investments.</p> <p>Past presenters have reported the following results:</p> <ul style="list-style-type: none">• increase in stock values in the days following the presentation• financially beneficial partnerships as a result of presentation• development of new companies as a result of participation in meeting <p>To submit an abstract visit: https://asent.org/AnnualMeeting2024</p>
3:00pm - 3:30pm	Networking Break
3:30pm - 5:00pm	<p>Pipeline Presentations</p> <p>Submitted abstracts that most closely conform to the ASENT Abstract criteria, showcase new and emerging data with scientific or clinical impact and align with ASENT goals may also be selected for a 10-minute oral presentation (including 2 minute Q&A) at one of our Pipeline Presentation sessions. ASENT encourages abstracts from private, public and startup companies, foundations and government or academic labs that contain neurotherapeutic research results.</p> <p>To submit an abstract visit: https://asent.org/AnnualMeeting2024</p>
5:00pm - 6:00pm	Cocktail and Poster Reception
6:00pm - 8:00pm	<p>Neurotherapeutics Dinner Guest Speaker: Irfan Qureshi, M.D., CMO, Biohaven</p> <p>This dinner symposium is a combined effort of the Training in Neurotherapeutics Discovery and Development Course and the ASENT2024 Annual Meeting. All participants are welcome to attend.</p> <p>CHAIR: Michael Rogawski, MD, PhD, University of California, Davis CO-CHAIR: Andrew J. Cole, MD, F.R.C.P.(C.) Harvard Medical School/MGH</p>

MEETING OVERVIEW

THURSDAY, MARCH 14, 2024

7:00am - 8:00am	Registration and Breakfast
8:00am - 8:30am	Presidential Closing Day Remarks
8:30am - 10:00am	<p>Presidential Symposium: Pre-clinical to First in Human In Drug Development</p> <p>DESCRIPTION: This fireside chat will feature speakers from both a small independent academic startup as well as a speaker from a large pharmaceutical company to compare and contrast the similarities and differences in the preclinical process and infrastructure when developing a neurotherapeutic. This discussion will be moderated by ASENT President Andrew Cole, MD.</p> <p>CHAIR: Nathan Fountain, MD, University of VA School of Medicine CO-CHAIR: Andrew J. Cole, MD, F.R.C.P.(C.) Harvard Medical School/MGH</p> <p>FACULTY: Nathan Fountain, MD, University of Virginia Jim Doherty, PhD, Sage Therapeutics</p>
10:00am - 10:30am	Networking Break
10:30am -12:00 pm	<p>Symposium: Animal Models in Neurotherapeutics: the good, the bad and the ugly.</p> <p>DESCRIPTION: Choice of animal models in evaluating novel solutions in neurodegeneration (and neuroinflammation)</p> <p>CHAIR: Carolyn Tallon, PhD, AltPep CO-CHAIR: Amy Easton, PhD, Target ALS</p> <p>FACULTY: Amy Easton, Target ALS Stacey J. Sukoff Rizzo, PhD, University of Pittsburgh Cameron Metcalf, PhD, University of Utah Charles K. Meshu, PhD, Oregon Health and Science University</p>
10:30am -12:00 pm	<p>Symposium: Novel Delivery Systems in CNS</p> <p>DESCRIPTION: Oligonucleotides and antibodies are increasingly proposed to provide significant benefit for central nervous system disorders. These modalities offer great promise to change the course of a disease. However, delivery of these therapeutics remains a significant challenge as they don't readily penetrate the blood brain barrier and therefore, require invasive delivery mechanisms. Fundamental multidisciplinary research in blood-brain barrier biology and protein engineering is ongoing to fully appreciate the great promise of these therapeutic modalities. This symposium will highlight innovative approaches to improve biotherapeutics delivery to the brain.</p> <p>CHAIR: Ben Deverman, PhD, MIT and Harvard CO-CHAIR: Amir Tamiz, PhD, NINDS</p> <p>FACULTY: TBD</p>
	Meeting Concludes

PROGRAM COMMITTEE

CHAIRS

Sharon Tamir, Chair

Mitsubishi Tanabe Pharma America

Dietrich Haubenberger, MHSc, MD

Neurocrine

MEMBERS

C. Anthony Altar, PhD

Splice Therapeutics

Deena Andreola

Takeda

Enrique Carrazana, MD

Neurelis

Suhayl Dhib-Jalbut, MD,

Rutgers-Robert Wood Johnson

Medical School

Debra Ehrlich, MD, MS

NINDS

Gail Farfel, PhD

ProMIS Neurosciences

Aditya Joshi, MD

University of Pennsylvania

Michelle Manzo, MPH

UCB

Ludy Shih, MD, MMSc

Boston University Medical Campus

Amir Tamiz, PhD

NINDS

Carolyn Tallon, PhD

AltPep

ASENT 2024 ANNUAL MEETING



GLOBAL NEUROTHERAPEUTICS
CONFERENCE
MARCH 12 - 14, 2024

HYATT REGENCY BETHESDA,
BETHESDA, MD

Abstract Deadline

January 22, 2024

**[asent.org/
annualmeeting2024](https://asent.org/annualmeeting2024)**

Early Bird Deadline

December 31, 2023

**[asent.org/
annualmeeting2024](https://asent.org/annualmeeting2024)**

Hotel Reservation Deadline

February 10, 2024

**[asent.org/
annualmeeting2024](https://asent.org/annualmeeting2024)**

Register at asent.org/annualmeeting2024

